Antidepressants

Anti-Depressants Raise Relapse Risk

Patients who use anti-depressants are much more likely to suffer relapses of major depression than those who use no medication at all, concludes a McMaster researcher.

In a paper that is likely to ignite new controversy in the hotly debated field of depression and medication, evolutionary psychologist Paul Andrews concludes that patients who have used anti-depressant medications can be nearly twice as susceptible to future episodes of major depression.

Andrews, an assistant professor in the Department of Psychology, Neuroscience & Behaviour, is the lead author of a new paper in the Journal Frontiers of Psychology.

The meta-analysis suggests that people who have not been taking any medication are at a 25 per cent risk of relapse, compared to 42 per cent or higher for those who have taken and gone off an anti-depressant.

Andrews and his colleagues studied dozens of previously published studies to compare outcomes for patients who used anti-depressants compared to those who used placebos.
They analyzed research on subjects who started on medications and were switched to placebos, subjects who were administered placebos throughout their treatment, and subjects who continued to take medication throughout their course of treatment.

Andrews says anti-depressants interfere with the brain’s natural self-regulation of serotonin and other neurotransmitters, and that the brain can overcorrect once medication is suspended, triggering new depression.

Though there are several forms of anti-depressants, all of them disturb the brain’s natural regulatory mechanisms, which he compares to putting a weight on a spring. The brain, like the spring, pushes back against the weight. Going off antidepressant drugs is like removing the weight from the spring, leaving the person at increased risk of depression when the brain, like the compressed spring, shoots out before retracting to its resting state.

“We found that the more these drugs affect serotonin and other neurotransmitters in your brain — and that’s what they’re supposed to do — the greater your risk of relapse once you stop taking them,” Andrews says. “All these drugs do reduce symptoms, probably to some degree, in the short-term. The trick is what happens in the long term. Our results suggest that when you try to go off the drugs, depression will bounce back. This can leave people stuck in a cycle where they need to keep taking anti-depressants to prevent a return of symptoms.”

Andrews believes depression may actually be a natural and beneficial — though painful
— state in which the brain is working to cope with stress. [continue reading…]

In Defense of Antidepressants

Peter D. Kramer clinical professor of psychiatry at Brown University opines in The New York Times in defense of Antidepressants .

In terms of perception, these are hard times for antidepressants. A number of articles have suggested that the drugs are no more effective than placebos.

Last month brought an especially high-profile debunking. In an essay in The New York Review of Books, Marcia Angell, former editor in chief of The New England Journal of Medicine, favorably entertained the premise that “psychoactive drugs are useless.” Earlier, a USA Today piece about a study done by the psychologist Robert DeRubeis had the headline, “Antidepressant lift may be all in your head,” and shortly after, a Newsweek cover piece discussed research by the psychologist Irving Kirsch arguing that the drugs were no more effective than a placebo.

Could this be true? Could drugs that are ingested by one in 10 Americans each year, drugs that have changed the way that mental illness is treated, really be a hoax, a mistake or a concept gone wrong? link to continue reading the article

Source: New York Times

Depressive patients carrying the risk allele show volume reduction in certain regions of the hippocampus. Photo: MPI for Psychiatry

Max Planck scientists uncover surprising genetic links. Scientists from the Max Planck Institute for Psychiatry in Munich have compared the genomes of a total of 4,088 patients and 11,001 healthy control subjects from all over the world and identified a new risk gene variant for depression.

They were able to show for the first time that physiologically measurable changes can be observed in the brains of healthy carriers of this risk allele. Those changes affect a transporter protein involved in the production of an important neuronal transmitter. Given that traditional drugs interact with similar transporter molecules, the researchers are pinning great hopes on this factor as the target structure of future antidepressant medication. Scientists throughout the world have been trying to identify the genetic causes of depression for many years. [continue reading…]